Literature DB >> 7639085

Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiazepine-dependent patients.

U Tönne1, A J Hiltunen, B Vikander, K Engelbrektsson, H Bergman, I Bergman, H Leifman, S Borg.   

Abstract

Impairment on neuropsychological tests during steady-state drug use and withdrawal, and after discontinuation of benzodiazepines, was studied in primary benzodiazepine-dependent patients. One group of patients was tested before and the other group after the initiation of a gradual tapering-off of the drug, and both groups were tested approximately 1 year later. At the initial assessment, both groups of patients showed impairment on most of the tests of general intelligence and on several of the tests in the Halstead-Reitan battery, as well as on a test of nonverbal memory, in comparison with healthy controls. At follow-up the patient groups had reached the level of the control group. This study confirmed earlier observations of neuropsychological deficits in long-term benzodiazepine-using patients and demonstrated that these changes are at least partly reversible by discontinuing drug intake.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639085     DOI: 10.1111/j.1600-0447.1995.tb09786.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  4 in total

1.  Superadditive effects of ethanol and flunitrazepam: implications of using immunopharmacotherapy as a therapeutic.

Authors:  Jennifer B Treweek; Amanda J Roberts; Kim D Janda
Journal:  Mol Pharm       Date:  2010-09-17       Impact factor: 4.939

2.  Cognitive effects of long-term benzodiazepine use: a meta-analysis.

Authors:  Melinda J Barker; Kenneth M Greenwood; Martin Jackson; Simon F Crowe
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?

Authors:  Christiaan H Vinkers; Berend Olivier
Journal:  Adv Pharmacol Sci       Date:  2012-03-29

Review 4.  Mexazolam: clinical efficacy and tolerability in the treatment of anxiety.

Authors:  Hélder Fernandes; Ricardo Moreira
Journal:  Neurol Ther       Date:  2014-03-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.